BRPI0817427A8 - anticorpo anti-bst2 - Google Patents
anticorpo anti-bst2Info
- Publication number
- BRPI0817427A8 BRPI0817427A8 BRPI0817427A BRPI0817427A BRPI0817427A8 BR PI0817427 A8 BRPI0817427 A8 BR PI0817427A8 BR PI0817427 A BRPI0817427 A BR PI0817427A BR PI0817427 A BRPI0817427 A BR PI0817427A BR PI0817427 A8 BRPI0817427 A8 BR PI0817427A8
- Authority
- BR
- Brazil
- Prior art keywords
- present
- antibodies
- bst2
- antibody
- bst2d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpo anti-bst2 humana, método para sua produção e seu uso, polinucleotídeo, vetor, hibridoma e agente terapêutico a presente invenção refere-se a anticorpos anti-bst2 que foram selecionados usando, como um indicador, a ligação entre anticorpos antibst2 e diversas variantes com sp/icing do antígeno bst2 humano. como um resultado, os presentes inventores obtiveram com sucesso anticorpos anti-bst2 que reconhecem especificamente a bst2d, a qual foi reportada como sendo expressa em altos níveis em células cancerígenas. os anticorpos da presente invenção se ligam especificamente a células expressando bst2d. ligação de anticorpo não-específica a tecidos nãoalvo, a qual resulta na diminuição da concentração de anticorpo no sangue, pode ser prevenida usando os anticorpos da presente invenção terapeuticamente. alternativamente, a presente invenção proporciona agentes diagnósticos compreendendo um anticorpo da presente invenção, o qual detecta especificamente tecidos expressando bst2d.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007269470 | 2007-10-16 | ||
| PCT/JP2008/068794 WO2009051201A1 (ja) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0817427A2 BRPI0817427A2 (pt) | 2015-06-16 |
| BRPI0817427A8 true BRPI0817427A8 (pt) | 2019-01-29 |
Family
ID=40567462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817427A BRPI0817427A8 (pt) | 2007-10-16 | 2008-10-16 | anticorpo anti-bst2 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8529896B2 (pt) |
| EP (1) | EP2210939A4 (pt) |
| JP (1) | JP5558825B2 (pt) |
| KR (1) | KR20100090258A (pt) |
| CN (2) | CN104031150A (pt) |
| AU (1) | AU2008312858A1 (pt) |
| BR (1) | BRPI0817427A8 (pt) |
| CA (1) | CA2702939A1 (pt) |
| IL (1) | IL205073A (pt) |
| MX (1) | MX2010004251A (pt) |
| NZ (1) | NZ585394A (pt) |
| RU (1) | RU2010119450A (pt) |
| UA (1) | UA105760C2 (pt) |
| WO (1) | WO2009051201A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| EP2858648B1 (en) | 2012-06-07 | 2018-08-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
| US20150299315A1 (en) * | 2012-10-22 | 2015-10-22 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
| CA2903091C (en) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| US9968579B2 (en) | 2014-07-17 | 2018-05-15 | Beth Isreal Deaconess Medical Center, Inc. | ATRA for modulating Pin1 activity and stability |
| MX388181B (es) | 2014-07-22 | 2025-03-19 | Cb Therapeutics Inc | Anticuerpos anti-pd-1. |
| JP6909153B2 (ja) * | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗ｐｄ−ｌ１抗体 |
| WO2016145186A1 (en) | 2015-03-12 | 2016-09-15 | Beth Israel Deaconess Medical Center, Inc. | Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| CN107619443B (zh) * | 2016-07-14 | 2020-08-14 | 深圳宾德生物技术有限公司 | 抗人和鼠cd317的单克隆抗体及其制备方法和应用 |
| JP2023530997A (ja) * | 2020-06-19 | 2023-07-20 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US305121A (en) * | 1884-09-16 | Razor-strop | ||
| TW474991B (en) * | 1993-10-15 | 2002-02-01 | Toshio Hirano | Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof |
| HUP0001136A3 (en) | 1997-02-12 | 2002-02-28 | Chugai Pharmaceutical Co Ltd | Remedies for lymphocytic tumors |
| DE69929876T2 (de) | 1998-02-25 | 2006-08-10 | Chugai Seiyaku K.K. | Für hm1.24 antigen kodierendes gen und dessen promotor |
| WO2002057316A1 (en) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Novel monoclonal antibody |
| JP3986439B2 (ja) * | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| EP1378752A4 (en) | 2001-04-13 | 2004-08-04 | Chugai Pharmaceutical Co Ltd | METHOD FOR QUANTIFYING ANTIGEN EXPRESSION |
| EP1693069B1 (en) | 2003-10-10 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Remedy for solid tumor |
| JP4915919B2 (ja) | 2004-06-11 | 2012-04-11 | Ｓｂｉバイオテック株式会社 | インターフェロン産生細胞の活性調節剤 |
| WO2006013923A1 (ja) * | 2004-08-05 | 2006-02-09 | Ginkgo Biomedical Research Institute Co., Ltd. | 自己免疫疾患を伴う関節炎の治療剤 |
| WO2006054748A1 (ja) * | 2004-11-22 | 2006-05-26 | Ginkgo Biomedical Research Institute Co., Ltd. | 腎炎の治療剤 |
| US20080299128A1 (en) | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
-
2008
- 2008-10-16 AU AU2008312858A patent/AU2008312858A1/en not_active Abandoned
- 2008-10-16 CN CN201410162825.3A patent/CN104031150A/zh active Pending
- 2008-10-16 CN CN200880122043.XA patent/CN101952426B/zh not_active Expired - Fee Related
- 2008-10-16 UA UAA201005531A patent/UA105760C2/uk unknown
- 2008-10-16 KR KR1020107010635A patent/KR20100090258A/ko not_active Ceased
- 2008-10-16 JP JP2009538149A patent/JP5558825B2/ja not_active Expired - Fee Related
- 2008-10-16 WO PCT/JP2008/068794 patent/WO2009051201A1/ja not_active Ceased
- 2008-10-16 BR BRPI0817427A patent/BRPI0817427A8/pt not_active IP Right Cessation
- 2008-10-16 EP EP08838804A patent/EP2210939A4/en not_active Withdrawn
- 2008-10-16 NZ NZ585394A patent/NZ585394A/en not_active IP Right Cessation
- 2008-10-16 US US12/738,285 patent/US8529896B2/en not_active Expired - Fee Related
- 2008-10-16 CA CA2702939A patent/CA2702939A1/en not_active Abandoned
- 2008-10-16 RU RU2010119450/10A patent/RU2010119450A/ru unknown
- 2008-10-16 MX MX2010004251A patent/MX2010004251A/es active IP Right Grant
-
2010
- 2010-04-14 IL IL205073A patent/IL205073A/en not_active IP Right Cessation
-
2013
- 2013-08-22 US US13/973,930 patent/US20130336967A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5558825B2 (ja) | 2014-07-23 |
| JPWO2009051201A1 (ja) | 2011-03-03 |
| IL205073A0 (en) | 2010-11-30 |
| NZ585394A (en) | 2012-05-25 |
| CN101952426B (zh) | 2014-04-16 |
| WO2009051201A1 (ja) | 2009-04-23 |
| KR20100090258A (ko) | 2010-08-13 |
| US8529896B2 (en) | 2013-09-10 |
| BRPI0817427A2 (pt) | 2015-06-16 |
| EP2210939A1 (en) | 2010-07-28 |
| CN101952426A (zh) | 2011-01-19 |
| CN104031150A (zh) | 2014-09-10 |
| CA2702939A1 (en) | 2009-04-23 |
| EP2210939A4 (en) | 2012-08-08 |
| US20100278832A1 (en) | 2010-11-04 |
| AU2008312858A1 (en) | 2009-04-23 |
| MX2010004251A (es) | 2010-08-30 |
| RU2010119450A (ru) | 2011-11-27 |
| HK1153502A1 (en) | 2012-03-30 |
| IL205073A (en) | 2014-07-31 |
| UA105760C2 (uk) | 2014-06-25 |
| US20130336967A1 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| MX2010004251A (es) | Anticuerpo anti-bst2. | |
| CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
| BR112012012887A2 (pt) | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. | |
| AR092612A1 (es) | Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| BR112012013975B8 (pt) | anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo | |
| MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| BR112014018561A8 (pt) | Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo | |
| EA201070687A1 (ru) | Способ ингибирования лейкозных стволовых клеток | |
| BRPI0613279A8 (pt) | Anticorpo manoclonal isolado, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-cd19, método para inibir o crescimento de células tumorais expressando cd19, e método para depleção de celulas b num indivíduo | |
| BR112014003999A2 (pt) | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp | |
| BR112013027867A2 (pt) | "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit" | |
| BR112014007687A8 (pt) | Composiçâo farmacêutica de anticorpos para eliminação de antígenos no plasma | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| AR073775A1 (es) | Anticuerpos biespecificos anti-vegf/anti- ang -2 | |
| CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
| BR112014031689A2 (pt) | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| CL2013001468A1 (es) | Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: SBI BIOTECH CO., LTD. (JP) , CHUGAI SEIYAKU KABUSH Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20120000079/RJ DE 02/01/2012, E NECESSARIO APRESENTAR COMPLEMENTACAO DO VALOR DA GUIA RELATIVA AO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25B | Requested transfer of rights rejected |
Owner name: SBI BIOTECH CO., LTD. (JP) , CHUGAI SEIYAKU KABUSH |